Zuojin Wan Combined With Woonosan Fumarate for the Treatment of GRD Combined With Depression

Inclusion Criteria: 1. Aged between 18 and 65 years; 2. Fulfilment of western medical diagnostic criteria for GERD; 3. Meet the diagnostic criteria for mild depression; 4. Comply with the diagnostic criteria of Liver and Stomach Depression-Heat syndrome in Chinese medicine; 5. A score of 7-17 on the 17-item Hamilton Depression Scale (HAMD-17) (7-17 being mild depression); 6. Good compliance and autonomous behaviour; 7. No medications that may have an effect on the study, such as acid-suppressing agonists, were taken within 2 weeks prior to enrolment; Exclusion Criteria: 1. HP positive patients; 2. Other organic diseases of the digestive system, such as peptic ulcer, peptic tumour, peptic haemorrhage, liver, gallbladder and pancreas disease, intestinal obstruction and inflammatory bowel disease; 3. Systemic diseases affecting the dynamics of the digestive tract, such as diabetes mellitus, chronic renal insufficiency, connective tissue diseases, neurological lesions, etc; 4. Pathological diagnosis of the esophageal mucosa suggestive of moderate-to-severe heterogeneous hyperplasia; 5. Previous surgery resulting in a decrease in gastric acid or a history of oesophageal or gastric surgery; 6. Varicose veins in the esophagus or fundus of the stomach; 7. Persons with severe primary heart, brain, liver, lung, kidney, blood or serious disease affecting their survival; 8. Those with depression, suicidal tendencies and mental disorders who cannot cooperate; 9. Pregnant or breastfeeding women, or patients who have a plan to have children in the near future; 10. Taking drugs that have an effect on the results of this study within 2 weeks before participating in this study; 11. Allergy or adverse reaction to the study drug.